Fabrizio Conicella - Direttore Generale del Bioindustry Park Silvano Fumero - è intervenuto ad Explore Talks on Healthcare, che si è svolto giovedì 18 maggio presso il Polihub di Milano, con un contributo sul paradigma delle cure in medicina nel prossimo futuro.
Personalised Medicine Congress (EAPM) - Dr Derick Mitchell - November 2017ipposi
IPPOSI Chief Executive presented at the EAPM 2017 Conference in Belfast in the ‘Personalised Medicine and Public Health: Two Sides of the Same Coin?’ session.
Introduction given by Piet Stinissen, chairman of LifeTechLimburg, in the framework of the Interregiomeeting "Healthy Ageing" on the 3rd of October 2012, organised by LifeTechLimburg
Personalised Medicine Congress (EAPM) - Dr Derick Mitchell - November 2017ipposi
IPPOSI Chief Executive presented at the EAPM 2017 Conference in Belfast in the ‘Personalised Medicine and Public Health: Two Sides of the Same Coin?’ session.
Introduction given by Piet Stinissen, chairman of LifeTechLimburg, in the framework of the Interregiomeeting "Healthy Ageing" on the 3rd of October 2012, organised by LifeTechLimburg
Finn Medi Presentation study visit (Life Sciences Sector)TR3S PROJECT
Description of the FinnMedi company, an internationally operating company located in Finland and providing services related to research commercialization, business development and clinical research in the Life Sciences sector.
Marcel de Pender, Slimmer Leven 2010 “Regional Strategy in The Province Noord...Mindtrek
Overview presentation
• Introduction Brainport Region
• Societal changes, technological developments, regulatory
aspects
• Innovation network for Active & Healthy Ageing: Smart
Living”
• Projects & spin-outs companies
• Cooperation
Slimmer Leven 2020
Innovation network for Active
and Healthy Ageing
Presented by:
Marcel de Pender,
Program Director, Slimmer Leven 2020
International Technology Conference Mindtrek 2017
20th - 21st of September, 2017
Tampere, Finland
Presentation "Innovating for Health and Well-being" at WHO International Healthy Cities conference, Athens, Greece, 25/OCT/2014, Arto Holopainen, Development Director, Kuopio Innovation Ltd.
IPPOSI CEO Derick Mitchell delivered a presentation on Dec 6th 2019 at the Digital health Conference, organised as part of the Royal College of Physicians, Ireland
EU Clinical Trials Regulation - IPPOSI perspectiveipposi
IPPOSI CEO, Dr Derick Mitchell delivered a presentation on the EU Clinical Trials Regulation from the patients' perspective at the 20th International Conference on Pharmaceutical Medicine, Athens, Greece.
Jan Geissler - How Patient (Advocates) discuss Clinical Research on the Internetpatvocates
"How Patient (Advocates) discuss Clinical Research on the Internet", presented by Jan Geissler (Twitter @jangeissler) at DIA Clinical Forum in The Hague on 9 Oct 2012.
MAPS2018 Keynote address on EY report: Life Sciences 4.0 – Securing value thr...EY
Summary: This keynote address presented by Pamela Spence, EY Global Life Sciences Leader (pspence2@uk.ey.com) at MAPS 2018 – the annual meeting for Medical Affairs Professional Society – discusses our latest life sciences report and the industry demands for a customer-focused, data driven approach to health care. We describe the accelerating pace of change as technological advances and the escalating expectations of payers, physicians and patient consumers are combining to disrupt the life sciences business model. Data and algorithms that maximize health outcomes based on individual needs and preferences are becoming the ultimate health care consumable. To create value now and in a future that we call Life Sciences 4.0, life sciences companies must build – or participate in – interoperable information systems that collect, combine and share data. For more on our report, Progressions 2018 – Life Sciences 4.0, please go to www.ey.com/progressions
Derick Mitchell_Biobanking from the patient perspective.pdfipposi
IPPOSI CEO Derick Mitchell presented the patient perspective on biobanking at the 2023 WECAN Academy for Cancer Patient Advocates on July 2nd, 2023 in Frankfurt, Germany.
Examples of latest solutions in health care developments in Finland and in Ku...Games for Health Finland
Examples of latest solutions in health care developments in Finland and in Kuopio, presentation during Finnish (City of Kuopio)-Mosambique (City of Maputo) workshop in Kuopio, Finland. Arto Holopainen, Development Director, Kuopio Innovation Ltd.
Io Products provides a unique investment opportunity for small investors - in a market that is anticipated to become substantial if not explosive in the next decade.
Progettare esperienze per emozionare. La transizione dalla UX alla UI.Coppa+Landini
Roberto Falcone - Lead UX Designer di Musement - si è soffermato sugli aspetti legati allo User Interface Design (UI Design) come parte del processo di UX Design che si occupa prettamente degli aspetti legati alla presentazione visuale di un prodotto digitale.
More Related Content
Similar to From prevention to the chronic patient management
Finn Medi Presentation study visit (Life Sciences Sector)TR3S PROJECT
Description of the FinnMedi company, an internationally operating company located in Finland and providing services related to research commercialization, business development and clinical research in the Life Sciences sector.
Marcel de Pender, Slimmer Leven 2010 “Regional Strategy in The Province Noord...Mindtrek
Overview presentation
• Introduction Brainport Region
• Societal changes, technological developments, regulatory
aspects
• Innovation network for Active & Healthy Ageing: Smart
Living”
• Projects & spin-outs companies
• Cooperation
Slimmer Leven 2020
Innovation network for Active
and Healthy Ageing
Presented by:
Marcel de Pender,
Program Director, Slimmer Leven 2020
International Technology Conference Mindtrek 2017
20th - 21st of September, 2017
Tampere, Finland
Presentation "Innovating for Health and Well-being" at WHO International Healthy Cities conference, Athens, Greece, 25/OCT/2014, Arto Holopainen, Development Director, Kuopio Innovation Ltd.
IPPOSI CEO Derick Mitchell delivered a presentation on Dec 6th 2019 at the Digital health Conference, organised as part of the Royal College of Physicians, Ireland
EU Clinical Trials Regulation - IPPOSI perspectiveipposi
IPPOSI CEO, Dr Derick Mitchell delivered a presentation on the EU Clinical Trials Regulation from the patients' perspective at the 20th International Conference on Pharmaceutical Medicine, Athens, Greece.
Jan Geissler - How Patient (Advocates) discuss Clinical Research on the Internetpatvocates
"How Patient (Advocates) discuss Clinical Research on the Internet", presented by Jan Geissler (Twitter @jangeissler) at DIA Clinical Forum in The Hague on 9 Oct 2012.
MAPS2018 Keynote address on EY report: Life Sciences 4.0 – Securing value thr...EY
Summary: This keynote address presented by Pamela Spence, EY Global Life Sciences Leader (pspence2@uk.ey.com) at MAPS 2018 – the annual meeting for Medical Affairs Professional Society – discusses our latest life sciences report and the industry demands for a customer-focused, data driven approach to health care. We describe the accelerating pace of change as technological advances and the escalating expectations of payers, physicians and patient consumers are combining to disrupt the life sciences business model. Data and algorithms that maximize health outcomes based on individual needs and preferences are becoming the ultimate health care consumable. To create value now and in a future that we call Life Sciences 4.0, life sciences companies must build – or participate in – interoperable information systems that collect, combine and share data. For more on our report, Progressions 2018 – Life Sciences 4.0, please go to www.ey.com/progressions
Derick Mitchell_Biobanking from the patient perspective.pdfipposi
IPPOSI CEO Derick Mitchell presented the patient perspective on biobanking at the 2023 WECAN Academy for Cancer Patient Advocates on July 2nd, 2023 in Frankfurt, Germany.
Examples of latest solutions in health care developments in Finland and in Ku...Games for Health Finland
Examples of latest solutions in health care developments in Finland and in Kuopio, presentation during Finnish (City of Kuopio)-Mosambique (City of Maputo) workshop in Kuopio, Finland. Arto Holopainen, Development Director, Kuopio Innovation Ltd.
Io Products provides a unique investment opportunity for small investors - in a market that is anticipated to become substantial if not explosive in the next decade.
Similar to From prevention to the chronic patient management (20)
Progettare esperienze per emozionare. La transizione dalla UX alla UI.Coppa+Landini
Roberto Falcone - Lead UX Designer di Musement - si è soffermato sugli aspetti legati allo User Interface Design (UI Design) come parte del processo di UX Design che si occupa prettamente degli aspetti legati alla presentazione visuale di un prodotto digitale.
Venanzio Arquilla - Professore Associato del Politecnico di Milano e Direttore Scientifico del Corso di Alta Formazione in User Experience Design di POLI.design - ha focalizzato il proprio speech sulle caratteristiche dello UX Design, sui perimetri di intervento dello UX Designer, sui perché la UX ha assunto importanza all'interno delle organizzazioni, sugli ultimi trend del corporate design e sulle tipologie di professionisti che maggiormente si stanno avvicinando a questa nuova professione
Davide Genco - UX Designer freelance e Direttore Tecnico del Corso di Alta Formazione in User Experience Design - è entrato nel dettaglio delle sfumature e degli intrecci tra la professione dello UX e dello UI Designer. Ha poi condiviso diversi strumenti di lavoro utili alle due tipologie di professionalità.
La comunicazione interna nell'era multicanaleCoppa+Landini
Prendendo come esempio l'utilizzo di una mobile app, si analizzano i vari momenti in cui l'HR deve interagire con i dipendenti dell'azienda e le buone pratiche perchè questi momenti di comunicazione si rivelino efficaci ed efficienti. Analizzando il percorso che una presona affronta in azienda, a partire dall'onboarding fino alla chiusura del rapporto lavorativo, vediamo come l'utilizzo di mezzi tecnologici come piattaforme e/o app possano aumentare l'engagement dei dipendenti, facilitare alcune operazioni come i momenti di training e sviluppo della conoscenza, le comunicazioni tra gruppi di lavoro o di natura aziendale, facilitare i rapporti tra azienda e dipendenti.
L'intelligenza artificiale al servizio dell'HRCoppa+Landini
I vari ambiti di applicazione dell'intelligenza artificiale nell'ambito HR, ad esempio nel processo di selezione, la disambiguazione attraverso la conoscenza del contesto e la classificazione mostrata attraverso la classificazione dei cv.
L'agenda dell'HR per la digital transformation: presentazione della surveyCoppa+Landini
Attraverso lo strumento della survey vediamo come monitorare e misurare il peso della digital transformation del dipartimento HR e quanto questo influisce sugli altri dipartimenti aziendali.
HR digitalization: processi e progetti Coppa+Landini
Digitalizzare la funzione HR può significare dotarsi di determinati software per gestire processi organizzativi, può voler dire servirsi di meccanismi social nelle modalità di fare employer branding e/o outplacement, ma può anche voler dire fare gamification.
Questa presentazione si focalizza sul nostro approccio alla visione delle digital HR, comprensiva della fase "digital maturity assessment". Quest'ultima parte da una survey che fotografa il grado di competenze legate alla cittadinanza digitale delle persone (quindi competenze digitali sia professionali che personali), ai domain experts (modello delle competenze digitali dell'organizzazione) e agli "enablers", ovvero lo scouting di leader e champions all'interno dell'organizzazione.
L'ecosistema digitale di Siemens Healthineers: dall'analisi del dato alla med...Coppa+Landini
Matteo Moscatelli - Head of Digital & Enterprise Services Siemens Healthineers Italia - è intervenuto agli Explore Talks on "Healthcare" per condividere l'esperienza di un'organizzazione corporate e raccontare in che modo la medicina predittiva può migliorare le performance del sistema sanitario, riducendo al contempo costi e prestazioni e come si sta muovendo Siemens Healthineers in Italia nel portare innovazione in questo campo.
Informatica e Genetica per una vera precision medicine Coppa+Landini
L'intervento di Matteo Tiberi, Chief Strategy Officer di wHealth, è stato focalizzato sulle modalità con cui la dematerializzazione dei processi di cura, unita alle nuove tecniche di analisi dei profili genetici, possa portare alla reale applicazione della Precision Medicine.
Sistemi indossabili per la salute e il benessere della personaCoppa+Landini
Giuseppe Andreoni, Direttore del Master in Design del Sistema Prodotto Servizio per la Sanità, Politecnico di Milano-POLI.design, è intervenuto ad Explore Talks on Healthcare, fornendo un consistente contributo sull'ecosistema dei sistemi indossabili in ambito healthcare.
Chiara Riccobene, Program Manager dello spinoff del Dipartimento di Matematica del Politecnico di Milano Moxoff,
ha raccontato il primo grande progetto che la società sta sviluppando in ambito "healthcare". aXurge, questo il suo nome, è una piattaforma che supporta lo specialista vascolare nel trattamento dell'aneurisma aortico addominale. Grazie a innovativi algoritmi matematici, aXurge permette di analizzare al meglio le informazioni, e aiuta il medico nella configurazione dell'eventuale intervento.
Marcello Coppa - CEO di Coppa+Landini - è intervenuto come primo speaker di Explore Talks on Healthcare (svoltosi giovedì 18 maggio presso il Polihub di Milano) per dare alla platea alcuni primi elementi di ispirazione riguardo il design thinking e l'innovazione applicati all'ambito della salute umana.
Message in a chatbot. I bot tra hype e realtà, come interfaccia conversaziona...Coppa+Landini
L'intervento di Fabio Malagnini, CMO & Co-founder di Botfarmy - startup che progetta chatbot - si è concentrato sulle aspettative create dal settore dell'intelligenza artificiale e sulla famiglia di tecnologie legata ai chatbot.
Il discorso dei chatbot si inserisce nell'ambito delle interfacce come conversazioni credibili. I punti maggiormente discussi durante il talk sono l'utilità di questo tipo di mezzo, i settori maggiori di utilizzo e il perché sono già considerate "le nuove app". Malagnini ha concluso il suo intervento presentando alcuni filoni applicativi, come l'ambito editoriale e i chatbot associati a servizi di e-commerce.
Lo scenario più interessante che si prospetta sarà costituito da interfacce sufficientemente sofisticate che cambieranno il workflow all'interno delle organizzazioni.
Francesco Inguscio, CEO di Nuvolab, ha fatto un intervento con un taglio "filosofico" sul futuro dell'umanità con l'avvento esponenziale della robotica.
Partendo dal concetto di schiavitù e servitù nell'antichità, passando per quello di progresso, è arrivato ad affrontare le leggi (non lineari) che governano le tecnologie, entrando nel merito di 3 di queste e gli effetti di un mondo che sta evolvendo alla velocità della luce sulla vita delle persone con una serie di best practice internazionali di robotica e intelligenza artificiale nei settori più disparati: dalla ristorazione al mondo legale, dal giornalismo al banking etc. La presentazione si conclude con una lettura in chiave positiva sul futuro di un'umanità che sarà "affollata" dai robot.
Michele Berra, Digital Marketing Manager Banca Mediolanum e Vincenzo Anitra, Marketing Canali Diretti Banca Mediolanum sono intervenuti all'Explore Talk on "Ro-bots" organizzato da Coppa+Landini il 1 marzo 2017 in Copernico Milano.
Il business model di Mediolanum è tale da aver favorito, a partire dal 2013, l'introduzione di sistemi di interazione vocale come Nuance (assistenza virtuale ad interazione vocale che permetteva di accedere rapidamente a tutte le informazioni contenute nell'applicazione mobile di Banca Mediolanum). Il passo successivo è stato integrare NINA (Nuance Interactive Natural Assistant) su mobile, di cui Michele Berra ha condiviso un video di presentazione.
Più avanti è stato creato internamente un assistente virtuale (chatbot) su facebook in versione basic, per via della facilità di utilizzo, di sviluppo, di tracciatura dei dati con Analitycs. Il chatbot di Mediolanum conosce in parte le esigenze del cliente o potenziale prospect.
L'intervento si è concluso con la demo del Facebook Messenger Chatbot di Mediolanum da parte di Vincenzo Anitra.
La nuova era dei robots: grandi opportunità e rischiCoppa+Landini
Andrea Forni, Fondatore di Investirobot - Osservatorio sugli Investimenti in Robotica - e del Meetup Italiano di Robotica, è intervenuto all'Explore Talk on "Ro-bots" organizzato da Coppa+Landini il 1 marzo 2017 in Copernico Milano.
Ha condiviso con il pubblico insight sul mercato della robotica fisica e di processo, sulla crescita del mercato dei roboadvisor e delle auto a guida autonoma. Sono tutti ambiti che si prospettano come opportunità di investimento interessanti per i prossimi 10 anni.
Si sta prospettando uno scenario per cui, da un lato si stima che sono stati creati 10 milioni di posti di lavoro grazie alla robotica, dall'altro che in un futuro non molto lontano circa il 47% dei lavori umani verranno sostituiti dall'intelligenza artificiale.
Una fetta consistente del nuovo mercato è costituito dalle società che producono droni e software per droni, società di servizi collegati ai droni e società assicurative collegate al rischio volo.
Explore Talks on "Maps" - 26 gennaio 2017 | Fulvio Iori, Co-founder & Business Development Mapadore / GoCloud, ha una particolare passione per le mappe da quando era bambino.
Questa sua passione lo ha condotto, insieme ai suoi soci, a fondare GoCloud, SaaS B2B che negli anni si è evoluto in un software as a service che permette l'efficientamento operativo delle forze vendita attraverso una serie di abbinamenti algoritmici di geo-ottimizzazione.
Una bella storia di passione che è diventata lavoro e startup.
Explore Talks on "Maps" - 26 gennaio 2016 | L'intervento di Massimiliano M. Cucciniello, UX/UI Designer di Coppa+Landini, ha avuto come focus le interfacce navigabili per accedere ad un sistema definito di servizi o a mondi immaginari.
Dai chips del futuro ai nostri corpi umani come dispositivi: si è parlato anche delle prospettive futuristiche di accesso alle mappe.
Costruire mappe per i progetti di territorio: interpretare contesti e "comunità"Coppa+Landini
Explore Talks on "Maps" - 26 gennaio 2017 | L'intervento di Massimo Carta, architetto e urbanista con un PhD in Progettazione urbana, territoriale ed ambientale presso l'Università di Firenze è stata un'esplorazione tra fonti, parole chiave, alcuni nodi problematici e alcune direzioni di ricerca sulle mappe, tra cui le mappe emozionali e le mappe di comunità. Massimo Carta è anche vicepresidente dello spin-off accademico "Mhc - progetto di territorio" dell'Università di Firenze. L'acronimo sta per "mapping hyperlocal communities", realtà con la mission di introdurre innovazione in metodi e strumenti di rappresentazione interattiva per accrescere l’efficacia dei processi partecipati di trasformazione urbana e territoriale (http://www.urbanisticapartecipata.org/).
These lecture slides, by Dr Sidra Arshad, offer a quick overview of physiological basis of a normal electrocardiogram.
Learning objectives:
1. Define an electrocardiogram (ECG) and electrocardiography
2. Describe how dipoles generated by the heart produce the waveforms of the ECG
3. Describe the components of a normal electrocardiogram of a typical bipolar leads (limb II)
4. Differentiate between intervals and segments
5. Enlist some common indications for obtaining an ECG
Study Resources:
1. Chapter 11, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 9, Human Physiology - From Cells to Systems, Lauralee Sherwood, 9th edition
3. Chapter 29, Ganong’s Review of Medical Physiology, 26th edition
4. Electrocardiogram, StatPearls - https://www.ncbi.nlm.nih.gov/books/NBK549803/
5. ECG in Medical Practice by ABM Abdullah, 4th edition
6. ECG Basics, http://www.nataliescasebook.com/tag/e-c-g-basics
micro teaching on communication m.sc nursing.pdfAnurag Sharma
Microteaching is a unique model of practice teaching. It is a viable instrument for the. desired change in the teaching behavior or the behavior potential which, in specified types of real. classroom situations, tends to facilitate the achievement of specified types of objectives.
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
New Drug Discovery and Development .....NEHA GUPTA
The "New Drug Discovery and Development" process involves the identification, design, testing, and manufacturing of novel pharmaceutical compounds with the aim of introducing new and improved treatments for various medical conditions. This comprehensive endeavor encompasses various stages, including target identification, preclinical studies, clinical trials, regulatory approval, and post-market surveillance. It involves multidisciplinary collaboration among scientists, researchers, clinicians, regulatory experts, and pharmaceutical companies to bring innovative therapies to market and address unmet medical needs.
New Directions in Targeted Therapeutic Approaches for Older Adults With Mantl...i3 Health
i3 Health is pleased to make the speaker slides from this activity available for use as a non-accredited self-study or teaching resource.
This slide deck presented by Dr. Kami Maddocks, Professor-Clinical in the Division of Hematology and
Associate Division Director for Ambulatory Operations
The Ohio State University Comprehensive Cancer Center, will provide insight into new directions in targeted therapeutic approaches for older adults with mantle cell lymphoma.
STATEMENT OF NEED
Mantle cell lymphoma (MCL) is a rare, aggressive B-cell non-Hodgkin lymphoma (NHL) accounting for 5% to 7% of all lymphomas. Its prognosis ranges from indolent disease that does not require treatment for years to very aggressive disease, which is associated with poor survival (Silkenstedt et al, 2021). Typically, MCL is diagnosed at advanced stage and in older patients who cannot tolerate intensive therapy (NCCN, 2022). Although recent advances have slightly increased remission rates, recurrence and relapse remain very common, leading to a median overall survival between 3 and 6 years (LLS, 2021). Though there are several effective options, progress is still needed towards establishing an accepted frontline approach for MCL (Castellino et al, 2022). Treatment selection and management of MCL are complicated by the heterogeneity of prognosis, advanced age and comorbidities of patients, and lack of an established standard approach for treatment, making it vital that clinicians be familiar with the latest research and advances in this area. In this activity chaired by Michael Wang, MD, Professor in the Department of Lymphoma & Myeloma at MD Anderson Cancer Center, expert faculty will discuss prognostic factors informing treatment, the promising results of recent trials in new therapeutic approaches, and the implications of treatment resistance in therapeutic selection for MCL.
Target Audience
Hematology/oncology fellows, attending faculty, and other health care professionals involved in the treatment of patients with mantle cell lymphoma (MCL).
Learning Objectives
1.) Identify clinical and biological prognostic factors that can guide treatment decision making for older adults with MCL
2.) Evaluate emerging data on targeted therapeutic approaches for treatment-naive and relapsed/refractory MCL and their applicability to older adults
3.) Assess mechanisms of resistance to targeted therapies for MCL and their implications for treatment selection
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
Explore natural remedies for syphilis treatment in Singapore. Discover alternative therapies, herbal remedies, and lifestyle changes that may complement conventional treatments. Learn about holistic approaches to managing syphilis symptoms and supporting overall health.
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Surat @ℂall @Girls ꧁❤8527049040❤꧂@ℂall @Girls Service Vip Top Model Safe
From prevention to the chronic patient management
1.
2. Science Park and cluster managing company
focused on life sciences and health, created with
the support of Regione Piemonte in the EU
programs framework (beginning 90’s) -
Operational since 1998.
§ 25.000 sqm labs, office spaces
§ R&D shared facilities and services
§ Support and acceleration of start-up/spin
off
§ Consultancy in biomanagement
§ Networking and clustering(bioPmed)
§ Conference centre
www.bioindustrypark.eu
Key elements
Bioindustry Park
Silvano Fumero
3. The Bioindustry Park
value creation process
From the identification of promising scientific
results to the growth of a successful company:
• Incubation
• Acceleration
• Settlements
• Managerial consulting
• Clustering
• International projects
• Scientific support (outsourced)
Incubation and company
acceleration
Facility management
and General services
for lessees
Exploitation of
scientific results and
scientific services
Consulting, TT
support, Cluster
development and
International
projects
4. The Italian health
care system
• In 2000 Italy's healthcare system was regarded,
by World Health Organization's ranking, as the
2nd best in the world after France
• Healthcare is provided to all citizens and
residents by a mixed public-private system. The
public part is the national health service,
“Sistema sanitario nazionale (SSN)”, which is
organized under the Ministry of Health and is
administered on a regional basis.
5. The vision for the future
of health management
Strategic Trajectories
Areas of Scientific
& Industrial Interest
Ageing and
chronic
pathologies
Converging
technologies
Personalised
approach and
integration of
therapy
/diagnosis
New
diagnostic
systems
Prevention
Innovative
medicines and
therapeutic
approaches
E-Health
• “”4Ps” paradigm approach
• “Patient-centric” approach
• “Value based” approach
6. Health care ecosystem
Source: https://www.linkedin.com/pulse/rise-chief-
ecosystem-officer-new-leaders-innovation-health-lawer
8. Personalised medicine
• Genetically-determined drug response
variability
• Increased safety and efficacy
• Pharmacogenetics represents an
‘evolution’ not a ‘revolution’ in
medicine
• Increased presence of personalised
medicine, not just at a genetic level
9. “Disruptive” role of IT
▫Innovation and change element:
▫Management/analysis/visualization
of data;
▫“Ubiquitous” health management;
▫ IoT;
Source: http://qnphc.org/personalized-health-care/
10. Consequences
on the health system
• Citizens are considered in general if they
have a disease
• Patients are not empowered
• Hospitalization is the “usual” way to manage
care
• Private providers are a “premium” or a “low
cost”choice and they are solution suppliers
• Health care is based on cost management
• The citizen is considered life long
• “4ps” approach: hospitalization for
acute phases and personalized
treatment
• Advanced prevention, diagnostic,
monitoring systems
• New role for families, society and
private providers
• Health care is based on value
management
Prevention and care management
health care models
Acute phase health care models
11. Consequences at
patient level
Elements:
• Patient Empowerment
• Life long health management
• Prevention/prediction as priority
• …….
Issues:
• Privacy
• Decision power
• Cost/sustainability
• ……..
13. Potential opportunities for companies
New market and innovation spaces and segments e.g.
Biotech and combined products (therapeutics and diagnostics)
Telemonitoring
Private diagnostic services
New models to “manage” elderly
Prediction through analysis of genomic data
Wereables and implantables devices
Social innovation solutions for chronic diseases
14. A possible example…
Source: Josip Car, Woan Shin Tan, Zhilian Huang, Peter Sloot and Bryony Dean Franklin “eHealth in the future of medications management:
personalisation, monitoring and adherence”, BMC Medicine201715:73
16. It is the team that wins, not
the single player
Bioindustry Park Silvano Fumero SpA
bioPmed Health Cluster
Via Ribes, 5
10010 Colleretto Giacosa (TO)
Italy
Tel. +39-0125-561311
www.bioindustrypark.eu
Info@bioindustrypark.it
www.biopmed.eu
info@biopmed.eu
Fabrizio Conicella
conicella@bioindustrypark.it
Thank you